How Mounjaro Works
Mounjaro MOA video ||| h6
Coming soon
Select Important Safety Information
Acute Gallbladder Disease ||| mounjaro-purple
In clinical trials, acute gallbladder disease was reported by 0.6% of Mounjaro-treated patients and 0% of placebo-treated patients. If cholelithiasis is suspected, gallbladder diagnostic studies and appropriate clinical follow-up are indicated.
Mounjaro works differently than a GLP-1 RA1
Tirzepatide is the first and only approved single molecule that activates GIP and GLP-1 receptors in the body.1
Mounjaro acts in the following ways1

1. ENHANCES
insulin secretion

2. IMPROVES
insulin sensitivity.

3. DECREASES
food intake.
Additional actions include delayed gastric emptying*and reduced glucagon levels.
Resulting in lower glucose concentration in both fasting and postprandial states.
*This effect diminishes over time.
GIP=glucose-dependent insulinotropic polypeptide; GLP-1=glucagon-like peptide-1; RA=receptor agonist; T2D=type 2 diabetes.
Reference:
- Mounjaro. Prescribing Information. Lilly USA, LLC.